Day: May 6, 2020

Paris, May 06, 2020, 2pmAB Science granted authorization by French Medicine Agency (ANSM)to initiate Phase 2 study evaluating masitinib in combination with isoquercetinfor the treatment of COVID-19Company to host live webcast on Monday May 11, 2020, 5.30pm CETAB Science SA (NYSE Euronext – FR0010557264 – AB) today announces initiation of a Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19, following rapid review and acceptance received from the French Medicine Agency, ANSM.This study (AB20001) is a randomized (1:1), open-label Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19.The study will enroll 200 patients (age ≥18 without an upper age limit) at medical centers in France...

Paris, 6 mai 2020, 14hAB Science a reçu l’autorisation de l’Agence française du médicament (ANSM)d’initier une étude de phase 2 évaluant le masitinib en combinaison avec l’isoquercetine dans le traitement du COVID-19AB Science tiendra une conférence web le lundi 11 mai 2020 à 17h30 CETAB Science SA (NYSE Euronext – FR0010557264 – AB) annonce aujourd’hui le lancement d’une étude de phase 2 évaluant le masitinib en combinaison avec l’isoquercétine dans le traitement du COVID-19, suite à l’évaluation accélérée et l’autorisation du protocole par l’Agence française du médicament, l’ANSM.Cette étude (AB20001) est une étude clinique de phase 2 randomisée (1:1), ouverte, visant à évaluer la tolérance et l’efficacité du masitinib associé à l’isoquercétine chez les patients hospitalisés atteints de COVID-19...

SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results and provide a corporate update after the market close on Tuesday, May 12, 2020.Conference Call and Webcast Details:Tuesday, May 12th @ 5:00 p.m. EDT / 2:00 p.m. PDTDomestic:  844-358-9116International:  209-905-5951Conference ID:  1375605Webcast: http://investors.atyrpharma.com/events-and-webcastsAbout aTyraTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular...

Revenue    º  26.9% increase in Q1 2020 revenue to $97.9 millionNet Cash from Operating Activities    º  $30.5 million in Q1 2020Adjusted EBITDA    º  36.3% increase in Q1 2020 Adjusted EBITDA to $56.2 millionLiquidation of Navios Europe II Inc. expected in Q2 2020Returning capital to stockholders:    º  Quarterly dividend: $0.30 per shareMONACO, May 06, 2020 (GLOBE NEWSWIRE) — Navios Maritime Acquisition Corporation (“Navios Acquisition”) (NYSE: NNA), an owner and operator of tanker vessels, reported its financial results today for the first quarter ended March 31, 2020.Angeliki Frangou, Chairman and Chief Executive Officer of Navios Acquisition stated, “While the humanitarian crises caused by the Pandemic has been heartbreaking, we have also been strengthened by the courage and compassion of the first responders, particularly...

CAMBRIDGE, Mass. and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the Bank of America Global Research Health Care Conference 2020. The presentation will take place on Tuesday, May 12, 2020, at 4:20 PM ET.About Black DiamondBlack Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein...

ROCKFORD, Mich., May 06, 2020 (GLOBE NEWSWIRE) — Wolverine World Wide, Inc. (NYSE: WWW) (the “Company”) today announced that it is offering $300 million aggregate principal amount of senior notes due 2025 (the “Notes”), subject to market and other customary conditions. The Company intends to use the net proceeds from the offering to repay borrowings under its revolving credit facility. The Notes will be guaranteed by the Company’s domestic subsidiaries that guarantee its senior credit facilities.The Notes and related guarantees will be offered only to persons believed to be qualified institutional buyers under Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”), and to non-U.S. persons in transactions outside the United States under Regulation S of the Securities Act. The Notes have not been registered under...

TORONTO, May 06, 2020 (GLOBE NEWSWIRE) — Gowest Gold Ltd. (“Gowest” or the “Company”) (TSX VENTURE: GWA) announced today that it has received the balance of the bridge loan agreement (the “Agreement”) entered into with Lush Land Investment Canada Inc. (“Lush Land”) for a loan facility of C$1.6 million (see News Release dated April 6, 2020).The purpose of the Agreement is to enable Gowest to continue to move ahead with its Advanced Exploration Bulk Sample program at the Company’s 100% owned Bradshaw Gold Deposit (“Bradshaw”) while the Company continues to work towards a significantly larger financing. Gowest continues discussions with interested parties regarding one or more financings to raise sufficient funds to complete the bulk sample and take Bradshaw immediately into production.Bradshaw UpdateThe Company has started the construction...

Hadar Levy Promoted to Senior Vice President and General Manager of North AmericaCompany Appoints Seasoned Medical Technology Finance Professional, Judith Huber, as Senior Vice President and Chief Financial OfficerPATTERSON, N.J. and JERUSALEM, May 06, 2020 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Hadar Levy has been promoted to Senior Vice President and General Manager of North America, and Judith Huber has been appointed the Company’s Senior Vice President and Chief Financial Officer, effective May 11, 2020.  Mr. Levy will oversee BrainsWay’s North American business, including sales, operations, customer service, field engineering, and customer training.  He is the Company’s current...

TORONTO, May 06, 2020 (GLOBE NEWSWIRE) — Ascendant Resources Inc. (TSX: ASND) (“Ascendant” or the “Company”) is pleased to announce that Mr. Rui Botica Santos is joining the Company’s Board of Directors. Mr. Santos is a lawyer based in Portugal who is widely regarded as a leading authority in the mining sector in Portugal. Mr. Santos has spent over 20 years representing/assisting domestic and international corporations in negotiations and disputes with the State regarding land acquisitions, exploration, extraction and environmental licenses, for both the mining and oil and gas industries in Portugal, Angola, Brazil and East Timor. Most notably, he was the legal advisor for major privatization transaction regarding the acquisition of Somincor by EuroZinc, which is now Lundin Mining’s Portuguese subsidiary...